RS12672 mitra adhami 11 resizedClinical research trials are an integral part of the advancement in medicine for both the treatment and prevention of infectious diseases. These trials serve to discover whether or not a particular treatment or preventative is safe and effective. All new drugs and medical devices must go through the process of clinical trials before being approved, produced, and marketed for the general public; thus, it is ultimately our volunteers whom help us understand, prevent, and treat communicable diseases.

A common misconception about clinical research trials is that only people who are sick or have a disease participate in them. Clinical trials, however, need people from all types of backgrounds for studies, including those who are healthy and those who have an illness or disease. Healthy people may choose to participate because they know someone who is affected by a particular illness or disease, or they may participate for philanthropic reasons. Participants who are sick or have a disease may also want to help others; however, being in a clinical research trial provides them with a chance to receive a new treatment as well as additional medical care and attention specifically for their ailment.

No matter the reason for joining a clinical research trial, just remember: With your help, we can bring an end to many infectious diseases throughout the world! Be the change...

Click below to view our upcoming and currently enrolling research studies. For a printable Clinical Research Trial Guide, click here.
 

Industry Studies

Anticipated Start: Summer 2019

 
 
Bavarian Nordic RSV is anticipated to be a Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of the Recobinant MVA-BN RSV vaccine after intranasal and intramuscular administration. RSV: Respiratory Syncytical Virus

Eligibility criteria has not yet been determined and will be updated as received.

If interested in placement on the wait-list for this study, please contact us via phone or the web.

Limited Space Available!

 
The Flu Vaccine study is a Phase II study assessing safety, reactogenicity, and immunogenicity of a Sanofi Pasteur A/H7N9 inactivated Influenza vaccine administered intramuscularly with or without AS03 adjuvant.

This study is open to healthy, HIV-negative adults aged 19 to 64 years old. Females able to become pregnant must be willing to use a medically accepted contraceptive method from 30 days before first vaccination until 60 days after the last study vaccination. Participation in this study will last approximately 13 months with up to 8 scheduled clinic visits and 2-7 phone calls depending on which group you are randomized into.

Other inclusion criteria applies. Compensation is provided after enrollment for those who qualify. This study will enroll rapidly over a 12 week period once open. If interested in participating, it is recommended that you contact us immediately to be placed on the wait-list for eligibility screening.

For more information or to be placed on the wait-list for this study, please contact us via phone or the web.
 
   

Prevention Studies

 

 
 
HVTN 121 is a Phase Ib open label clinical trial to evaluate HIV-1 neutralization on antibody breadth in response to HIV gp120 protein vaccine in HIV-uninfected adults with quiescent Systemic Lupus Erthematosus.

Additional information is not available at this time. Please check back later for updates and eligibility criteria.
              

Microbicide Studies

MTN 035 is a Phase I study.
 

Researchers are interested in developing a rectal product to protect against HIV infection during anal sex. This study is being done to see what kinds of products people would prefer to use before anal sex— a douche, an insert, or a suppository. Participants will be asked to use each product for a period of 1 month and complete surveys about their opinion and experiences with each one. There is no active drug in any of the products being used. The study lasts about 3 months, and involves a total of 8 visits. You will be compensated for your time.

.
 
    
MTN 037 is a Phase I study.

The purpose of the study is to test the safety and acceptability of a new rectal gel, which is being developed to protect against HIV infection during anal sex.  If you are HIV negative and have had anal sex at least once in your life, you may be eligible to participate. The study involves 9 visits over a period of about 3-5 months. During this time, participants will insert the gel, rectally, a total of 3 times. Rectal biopsies will be collected at 5 of the visits. You will be compensated for your time.